Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

NCT03703596 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Lung Cancer Metastatic

Interventions

DRUG: Anlotinib Hydrochloride
DRUG: Docetaxel

Sponsor

Sichuan Cancer Hospital and Research Institute

Collaborators

[object Object]